Skip to main content
SpringerLink
Log in

Auditory Late Effects of Chemotherapy

  • Chapter
  • First Online:
Late Effects of Treatment for Brain Tumors

Part of the book series: Cancer Treatment and Research ((CTAR,volume 150))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Fausti SA, Schechter MA, Rappaport BZ, et al. Early detection of cisplatin ototoxicity. Selected case reports. Cancer. 1984;53:224 231.

    PubMed  CAS  Google Scholar 

  2. Bertolini P, Lassalle M, Mercier G, et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol. 2004;26:649 655.

    PubMed  Google Scholar 

  3. Kretschmar CS, Warren MP, Lavally BL, et al. Ototoxicity of preradiation cisplatin for children with central nervous system tumors. J Clin Oncol. 1990;8:1191 1198.

    PubMed  CAS  Google Scholar 

  4. Kushner BH, Budnick A, Kramer K, et al. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer. 2006;107:417 422.

    PubMed  CAS  Google Scholar 

  5. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer. 2004;40:2445 2451.

    PubMed  CAS  Google Scholar 

  6. Skinner R, Pearson AD, Amineddine HA, et al. Ototoxicity of cisplatinum in children and adolescents. Br J Cancer. 1990;61:927 931.

    PubMed  CAS  Google Scholar 

  7. Blakley BW, Myers SF. Patterns of hearing loss resulting from cis-platinum therapy. Otolaryngol Head Neck Surg. 1993;109:385 391.

    PubMed  CAS  Google Scholar 

  8. Brock PR, Bellman SC, Yeomans EC, et al. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol. 1991;19:295 300.

    PubMed  CAS  Google Scholar 

  9. Ilveskoski I, Saarinen UM, Wiklund T, et al. Ototoxicity in children with malignant brain tumors treated with the “8 in 1” chemotherapy protocol. Med Pediatr Oncol. 1996;27:26 31.

    PubMed  CAS  Google Scholar 

  10. Montaguti M, Brandolini C, Ferri GG, et al.[Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention]. Acta Otorhinolaryngol Ital. 2002;22:14 18.

    PubMed  CAS  Google Scholar 

  11. Bokemeyer C, Berger CC, Hartmann JT, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer. 1998;77:1355 1362.

    PubMed  CAS  Google Scholar 

  12. Parsons SK, Neault MW, Lehmann LE, et al. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant. 1998;22:669 674.

    PubMed  CAS  Google Scholar 

  13. Brown RL, Nuss RC, Patterson R, et al. Audiometric monitoring of cis-platinum ototoxicity. Gynecol Oncol. 1983;16:254 262.

    PubMed  CAS  Google Scholar 

  14. Schaefer SD, Post JD, Close LG, et al. Ototoxicity of low- and moderate-dose cisplatin. Cancer. 1985;56:1934 1939.

    PubMed  CAS  Google Scholar 

  15. Aguilar-Markulis NV, Beckley S, Priore R, et al. Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients. J Surg Oncol. 1981;16:111 123.

    PubMed  CAS  Google Scholar 

  16. Truong MT, Winzelberg J, Chang KW. Recovery from cisplatin-induced ototoxicity: a case report and review. Int J Pediatr Otorhinolaryngol. 2007;71:1631 1638.

    Google Scholar 

  17. Cohen BH, Zweidler P, Goldwein JW, et al. Ototoxic effect of cisplatin in children with brain tumors. Pediatr Neurosurg. 1990;16:292 296.

    PubMed  Google Scholar 

  18. Freilich RJ, Kraus DH, Budnick AS, et al. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue. Med Pediatr Oncol. 1996;26:95 100.

    PubMed  CAS  Google Scholar 

  19. Miettinen S, Laurikainen E, Johansson R, et al. Radiotherapy enhanced ototoxicity of cisplatin in children. Acta Otolaryngol Suppl. 1997;529:90 94.

    PubMed  CAS  Google Scholar 

  20. Schell MJ, McHaney VA, Green AA, et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol. 1989;7:754 760.

    PubMed  CAS  Google Scholar 

  21. Simon T, Hero B, Dupuis W, et al. The incidence of hearing impairment after successful treatment of neuroblastoma. Klin Padiatr. 2002;214:149 152.

    PubMed  CAS  Google Scholar 

  22. Canetta R, Rozencweig M, Carter SK. Carboplatin: the clinical spectrum to date. Cancer Treat Rev. 1985;12 Suppl A:125 136.

    PubMed  CAS  Google Scholar 

  23. Meyers FJ, Welborn J, Lewis JP, et al. Infusion carboplatin treatment of relapsed and refractory acute leukemia: evidence of efficacy with minimal extramedullary toxicity at intermediate doses. J Clin Oncol. 1989;7:173 178.

    PubMed  CAS  Google Scholar 

  24. Ettinger LJ, Gaynon PS, Krailo MD, et al. A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Children’s Cancer Group. Cancer. 1994;73:1297 1301.

    Google Scholar 

  25. Lambert MP, Shields C, Meadows AT. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer. 2008;50:223 226.

    PubMed  Google Scholar 

  26. Stern JW, Bunin N. Prospective study of carboplatin-based chemotherapy for pediatric germ cell tumors. Med Pediatr Oncol. 2002;39:163 167.

    PubMed  Google Scholar 

  27. Kennedy IC, Fitzharris BM, Colls BM, et al. Carboplatin is ototoxic. Cancer Chemother Pharmacol. 1990;26:232 234.

    PubMed  CAS  Google Scholar 

  28. Allen JRL. Modern-period muddy sediments in the severn estuary (Southwestern UK) A pollutant-based model for dating and correlation. Sedimentary Geol. 1988;58:1.

    CAS  Google Scholar 

  29. Macdonald MR, Harrison RV, Wake M, et al. Ototoxicity of carboplatin: comparing animal and clinical models at the Hospital for Sick Children. J Otolaryngol. 1994;23:151 159.

    PubMed  CAS  Google Scholar 

  30. Doolittle ND, Muldoon LL, Brummett RE, et al. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res. 2001;7:493 500.

    PubMed  CAS  Google Scholar 

  31. Williams PC, Henner WD, Roman-Goldstein S, et al. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Neurosurgery. 1995;37:17 27; discussion -8.

    PubMed  CAS  Google Scholar 

  32. Lugassy G, Shapira A. Sensorineural hearing loss associated with vincristine treatment. Blut. 1990;61:320 321.

    PubMed  CAS  Google Scholar 

  33. Aydogdu I, Ozturan O, Kuku I, et al. Bilateral transient hearing loss associated with vincristine therapy: case report. J Chemother. 2000;12:530 532.

    Google Scholar 

  34. Riga M, Psarommatis I, Korres S, et al. Neurotoxicity of vincristine on the medial olivocochlear bundle. Int J Pediatr Otorhinolaryngol. 2007;71:63 69.

    PubMed  CAS  Google Scholar 

  35. Moroso MJ, Blair RL. A review of cis-platinum ototoxicity. J Otolaryngol. 1983;12:365 369.

    PubMed  CAS  Google Scholar 

  36. Boheim K, Bichler E. Cisplatin-induced ototoxicity: audiometric findings and experimental cochlear pathology. Arch Otorhinolaryngol. 1985;242:1 6.

    PubMed  CAS  Google Scholar 

  37. Komune S, Asakuma S, Snow JB, Jr. Pathophysiology of the ototoxicity of cis-diamminedichloroplatinum. Otolaryngol Head Neck Surg. 1981;89:275 282.

    PubMed  CAS  Google Scholar 

  38. Hoistad DL, Ondrey FG, Mutlu C, et al. Histopathology of human temporal bone after cis-platinum, radiation, or both. Otolaryngol Head Neck Surg. 1998;118:825 832.

    PubMed  CAS  Google Scholar 

  39. Hinojosa R, Riggs LC, Strauss M, et al. Temporal bone histopathology of cisplatin ototoxicity. Am J Otol. 1995;16:731 740.

    PubMed  CAS  Google Scholar 

  40. Dehne N, Lautermann J, Petrat F, et al. Cisplatin ototoxicity: involvement of iron and enhanced formation of superoxide anion radicals. Toxicol Appl Pharmacol. 2001;174:27 34.

    PubMed  CAS  Google Scholar 

  41. Takeno S, Harrison RV, Ibrahim D, et al. Cochlear function after selective inner hair cell degeneration induced by carboplatin. Hear Res. 1994;75:93 102.

    PubMed  CAS  Google Scholar 

  42. Kwong DL, Wei WI, Sham JS, et al. Sensorineural hearing loss in patients treated for nasopharyngeal carcinoma: a prospective study of the effect of radiation and cisplatin treatment. Int J Radiat Oncol Biol Phys.1996;36:281 289.

    PubMed  CAS  Google Scholar 

  43. Walker DA, Pillow J, Waters KD, et al. Enhanced cis-platinum ototoxicity in children with brain tumours who have received simultaneous or prior cranial irradiation. Med Pediatr Oncol. 1989;17:48 52.

    PubMed  CAS  Google Scholar 

  44. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005;23:8588 8596.

    PubMed  Google Scholar 

  45. Huang E, Teh BS, Strother DR, et al. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys. 2002;52:599 605.

    Google Scholar 

  46. Weatherly RA, Owens JJ, Catlin FI, et al. Cis-platinum ototoxicity in children. Laryngoscope. 1991;101:917 924.

    PubMed  CAS  Google Scholar 

  47. McHaney VA TG, Hayes FA. Hearing loss in children receiving cisplatin chemotherapy. K Pediatr. 1983;83:314 317.

    Google Scholar 

  48. Pasic TR, Dobie RA. Cis-platinum ototoxicity in children. Laryngoscope. 1991;101:985 991.

    PubMed  CAS  Google Scholar 

  49. Rademaker-Lakhai JM, Crul M, Zuur L, et al. Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol. 2006;24:918 924.

    PubMed  CAS  Google Scholar 

  50. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748 1756.

    PubMed  CAS  Google Scholar 

  51. Peng B, English MW, Boddy AV, et al. Cisplatin pharmacokinetics in children with cancer. Eur J Cancer. 1997;33:1823 1828.

    PubMed  CAS  Google Scholar 

  52. Peng B BA, English MW, et al. The comparative pharmacokinetics and pharmacodynamics of cisplatin and carboplatin in paediatric patients: a review. Anticancer Res. 1994;14:2279 2283.

    Google Scholar 

  53. Posner MR, Ferrari L, Belliveau JF, et al. A phase I trial of continuous infusion cisplatin. Cancer. 1987;59:15 18.

    PubMed  CAS  Google Scholar 

  54. Erdlenbruch B, Nier M, Kern W, et al. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients. Eur J Clin Pharmacol. 2001;57:393 402.

    PubMed  CAS  Google Scholar 

  55. Humes HD. Insights into ototoxicity. Analogies to nephrotoxicity. Ann N Y Acad Sci. 1999;884:15 18.

    PubMed  CAS  Google Scholar 

  56. Dominici C, Petrucci F, Caroli S, et al. A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors. J Clin Oncol. 1989;7:100 107.

    PubMed  CAS  Google Scholar 

  57. Murakami T, Inoue S, Sasaki K, et al. Studies on age-dependent plasma platinum pharmacokinetics and ototoxicity of cisplatin. Sel Cancer Ther. 1990;6:145 151.

    PubMed  CAS  Google Scholar 

  58. Gupta AA, Capra M, Papaioannou V, et al. Low incidence of ototoxicity with continuous infusion of cisplatin in the treatment of pediatric germ cell tumors. J Pediatr Hematol Oncol. 2006;28:91 94.

    PubMed  CAS  Google Scholar 

  59. Lanvers-Kaminsky C, Krefeld B, Dinnesen AG, et al. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatr Blood Cancer. 2006;47:183 193.

    PubMed  CAS  Google Scholar 

  60. Oldenburg J, Kraggerud SM, Cvancarova M, et al. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol. 2007;25:708 714.

    PubMed  CAS  Google Scholar 

  61. Peters U, Preisler-Adams S, Hebeisen A, et al. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000;11:639 643.

    PubMed  CAS  Google Scholar 

  62. Kohn S, Fradis M, Podoshin L, et al. Ototoxicity resulting from combined administration of cisplatin and gentamicin. Laryngoscope. 1997;107:407 408.

    PubMed  CAS  Google Scholar 

  63. Coradini PP, Cigana L, Selistre SG, et al. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol. 2007;29:355 360.

    PubMed  CAS  Google Scholar 

  64. Hallmark RJ, Snyder JM, Jusenius K, et al. Factors influencing ototoxicity in ovarian cancer patients treated with Cis-platinum based chemotherapy. Eur J Gynaecol Oncol. 1992;13:35 44.

    PubMed  CAS  Google Scholar 

  65. Gaegcnti DL. Childhood. In: Finegold M, Beningtion J, eds. Pathology of Neoplasia in Children and Adults. Philadelphia: WB Saunders. 1986:282 312.

    Google Scholar 

  66. Buhrer C, Weinel P, Sauter S, et al. Acute onset deafness in a 4 year-old girl after a single infusion of cis-platinum. Pediatr Hematol Oncol. 1990;7:145 148.

    PubMed  CAS  Google Scholar 

  67. Berg AL, Spitzer JB, Garvin JH, Jr. Ototoxic impact of cisplatin in pediatric oncology patients. Laryngoscope. 1999;109:1806 1814.

    PubMed  CAS  Google Scholar 

  68. Skinner R. Best practice in assessing ototoxicity in children with cancer. Eur J Cancer. 2004;40:2352 2354.

    PubMed  Google Scholar 

  69. Northern JL, Downs MP. Hearing in Children, ed. Baltimore, MD: Williams & Wilkins, 1991

    Google Scholar 

  70. American Speech-Language-Hearing Association. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA. 2004;35(Suppl 12):11 19.

    Google Scholar 

  71. Bess FH, Dodd-Murphy J, Parker RA. Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status. Ear Hear. 1998;19:339 354.

    PubMed  CAS  Google Scholar 

  72. Schmidt CM, Bartholomäus E, Deuster D, et al. The Muenster classification of high frequency hearing loss following cisplatin chemotherapy. HNO 2007;55(4):299 306.

    Google Scholar 

  73. Stavroulaki P, Apostolopoulos N, Segas J, et al. Evoked otoacoustic emissions an approach for monitoring cisplatin induced ototoxicity in children. Int J Pediatr Otorhinolaryngol. 2001;59:47 57.

    PubMed  CAS  Google Scholar 

  74. Littman TA, Magruder A, Strother DR. Monitoring and predicting ototoxic damage using distortion-product otoacoustic emissions: pediatric case study. J Am Acad Audiol. 1998;9:257 262.

    PubMed  CAS  Google Scholar 

  75. Smith LJ, inventor Smith, L J (SMIT-Individual), assignee. Educational kit used for teaching paleontology to child. US. 1999 August 24.

    Google Scholar 

  76. Sockalingam R, Freeman S, Cherny TL, et al. Effect of high-dose cisplatin on auditory brainstem responses and otoacoustic emissions in laboratory animals. Am J Otol. 2000;21:521 527.

    PubMed  CAS  Google Scholar 

  77. Toral RM, Skurovitch-Bialik P, Collado-Corona MA, et al. Distortion product otoacoustic emissions test is useful in children undergoing cisplatin treatment. Arch Med Res. 2003;34:205 208.

    Google Scholar 

  78. Hotz MA, Harris FP, Probst R. Otoacoustic emissions: an approach for monitoring aminoglycoside-induced ototoxicity. Laryngoscope. 1994;104:1130 1134.

    PubMed  CAS  Google Scholar 

  79. Subramaniam M, Salvi RJ, Spongr VP, et al. Changes in distortion product otoacoustic emissions and outer hair cells following interrupted noise exposures. Hear Res. 1994;74:204 216.

    PubMed  CAS  Google Scholar 

  80. Dhooge I, Dhooge C, Geukens S, et al. Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives. Int J Audiol. 2006;45:337 343.

    PubMed  Google Scholar 

  81. Campbell KC, Kelly E, Targovnik N, et al. Audiologic monitoring for potential ototoxicity in a phase I clinical trial of a new glycopeptide antibiotic. J Am Acad Audiol. 2003;14:157 168; quiz 70 71.

    PubMed  Google Scholar 

  82. Ress BD, Sridhar KS, Balkany TJ, et al. Effects of cis-platinum chemotherapy on otoacoustic emissions: the development of an objective screening protocol. Third place Resident Clinical Science Award. 1998. Otolaryngol Head Neck Surg. 1999;121:693 701.

    PubMed  CAS  Google Scholar 

  83. Knight KR, Kraemer DF, Winter C, et al. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol. 2007;25:1190 1195.

    PubMed  CAS  Google Scholar 

  84. A. B. Room acoustics and speech perception. http://wwwwrohansdsuedu/aboothro/files/RoomAcoustics/Roomacousticsandspeechperceptionpdf, 2002.

  85. Stelmachowicz PG, Pittman AL, Hoover BM, et al. The importance of high-frequency audibility in the speech and language development of children with hearing loss. Arch Otolaryngol Head Neck Surg. 2004;130:556 562.

    PubMed  Google Scholar 

  86. Stelmachowicz PG, Pittman AL, Hoover BM, et al. Effect of stimulus bandwidth on the perception of /s/ in normal- and hearing-impaired children and adults. J Acoust Soc Am. 2001;110:2183 2190.

    PubMed  CAS  Google Scholar 

  87. French NR, Steinberg J. Factors governing the intelligibility of speech sounds. J Acoust Soc Am. 1947;19:90 119.

    Google Scholar 

  88. Katz J WT. Introduction to the Handicap of Hearing Impairment: Auditory Impairment Versus Hearing Handicap.San Diego, CA: Singular Publishing Group; 1982.

    Google Scholar 

  89. Smoluk GD, Fahey RC, Calabro-Jones PM, et al. Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection. Cancer Res. 1988;48:3641 3647.

    PubMed  CAS  Google Scholar 

  90. Schiller JH. High-dose cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer. Semin Oncol. 1996;23:78 82.

    PubMed  CAS  Google Scholar 

  91. Schuchter LM. Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol). Eur J Cancer. 1996;32A Suppl 4:S40 S42.

    Google Scholar 

  92. Hospers GA, Eisenhauer EA, de Vries EG. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. Br J Cancer. 1999;80:629 638.

    PubMed  CAS  Google Scholar 

  93. Block KI GC. Commentary: the pharmacological antioxidant amifostine implications of recent research for integrative cancer care. Integrative Cancer Therapies. 2005;4:325 351.

    Google Scholar 

  94. Hussain AE, Blakley BW, Nicolas M, et al. Assessment of the protective effects of amifostine against cisplatin-induced toxicity. J Otolaryngol. 2003;32:294 297.

    PubMed  Google Scholar 

  95. Ekborn A, Hansson J, Ehrsson H, et al. High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics. Laryngoscope. 2004;114:1660 1667.

    PubMed  CAS  Google Scholar 

  96. Marina N, Chang KW, Malogolowkin M, et al. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study. Cancer. 2005;104:841 847.

    PubMed  CAS  Google Scholar 

  97. Capizzi R. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol. 1996;23:2 17.

    PubMed  CAS  Google Scholar 

  98. Neuwelt EA, Brummett RE, Remsen LG, et al. In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity. Cancer Res. 1996;56:706 709.

    PubMed  CAS  Google Scholar 

  99. Neuwelt EA, Brummett RE, Doolittle ND, et al. First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate. J Pharmacol Exp Ther. 1998;286:77 84.

    PubMed  CAS  Google Scholar 

  100. Abe R, Akiyoshi T, Tsuji H, et al. Protection of antiproliferative effect of cis-diamminedichloroplatinum (II) by sodium thiosulfate. Cancer Chemother Pharmacol. 1986;18:98 100.

    PubMed  CAS  Google Scholar 

  101. Elferink F, van der Vijgh WJ, Klein I, et al. Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding. Clin Chem. 1986;32:641 645.

    PubMed  CAS  Google Scholar 

  102. Dickey DT, Wu YJ, Muldoon LL, et al. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther. 2005;314:1052 1058.

    PubMed  CAS  Google Scholar 

  103. Campbell KC, Rybak LP, Meech RP, et al. D-methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear Res. 1996;102:90 98.

    PubMed  CAS  Google Scholar 

  104. Reser D, Rho M, Dewan D, et al. L- and D- methionine provide equivalent long term protection against CDDP-induced ototoxicity in vivo, with partial in vitro and in vivo retention of antineoplastic activity. Neurotoxicology. 1999;20:731 748.

    PubMed  CAS  Google Scholar 

  105. Korver KD, Rybak LP, Whitworth C, et al. Round window application of D-methionine provides complete cisplatin otoprotection. Otolaryngol Head Neck Surg. 2002;126:683 689.

    PubMed  Google Scholar 

  106. Campbell KC, Meech RP, Rybak LP, et al. D-Methionine protects against cisplatin damage to the stria vascularis. Hear Res. 1999;138:13 28.

    PubMed  CAS  Google Scholar 

  107. Sequoia Ecosystem and Recreation Preserve Act of 1999. In. 106th Congress ed; 1999.

    Google Scholar 

  108. Wimmer C, Mees K, Stumpf P, et al. Round window application of D-methionine, sodium thiosulfate, brain-derived neurotrophic factor, and fibroblast growth factor-2 in cisplatin-induced ototoxicity. Otol Neurotol. 2004;25:33 40.

    PubMed  Google Scholar 

  109. Church MW, Kaltenbach JA, Blakley BW, et al. The comparative effects of sodium thiosulfate, diethyldithiocarbamate, fosfomycin and WR-2721 on ameliorating cisplatin-induced ototoxicity. Hear Res. 1995;86:195 203.

    PubMed  CAS  Google Scholar 

  110. Kaltenbach JA, Church MW, Blakley BW, et al. Comparison of five agents in protecting the cochlea against the ototoxic effects of cisplatin in the hamster. Otolaryngol Head Neck Surg. 1997;117:493 500.

    PubMed  CAS  Google Scholar 

  111. Copeland BJ, Pillsbury HC, 3rd. Cochlear implantation for the treatment of deafness. Annu Rev Med. 2004;55:157 167.

    PubMed  CAS  Google Scholar 

  112. Brock P, Pritchard J, Bellman S, Pinkerton CR. Ototoxicity of high-dose cisplatinum in children. Med Pediatr Oncol.1988;16:368 369.

    PubMed  CAS  Google Scholar 

  113. Brock P, Bellman S, Pritchard J. Ototoxicity of cisplatinum Br J Cancer.1991;63:159 161.

    PubMed  CAS  Google Scholar 

  114. Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J. Cisplatin ototoxicity in children; a practical grading system. Med Pediatr Oncol.1991;19:295 300.

    PubMed  CAS  Google Scholar 

  115. Brock P, Yeomans E, Bellman S, Pritchard J. Cisplatin therapy in infants: short and long-term morbidity. Br J Cancer. 1992;66:Suppl XVIII:S36 S40.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Otolaryngology, Department of Otolaryngology – Head & Neck Surgery, University of California, San Francisco, 400 Parnassus Avenue, Suite A730, 94143-0342, San Francisco, CA, USA

    Anna K. Meyer MD

  2. Section of Otology/Neurotology, Otolaryngology, Cochlear Implant Program and Audiology, Children’s Memorial Medical Center, 60614-3394, Chicago, IL, USA

    Nancy M. Young MD

  3. Northwestern University’s Feinberg School of Medicine, Children’s Memorial Medical Center, 2300 Children’s Plaza, 60614-3394, Chicago, IL, USA

    Nancy M. Young MD

Authors
  1. Anna K. Meyer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nancy M. Young MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anna K. Meyer MD .

Editor information

Editors and Affiliations

  1. Dept. Pediatrics, Children's Memorial Hospital, Children's Plaza 2300, Chicago, 30614, U.S.A.

    Stewart Goldman

  2. Dana-Farber Cancer Institute, Harvard Medical School, Binney St. 44, Boston, 02115, U.S.A.

    Christopher D. Turner

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Meyer, A.K., Young, N.M. (2009). Auditory Late Effects of Chemotherapy. In: Goldman, S., Turner, C. (eds) Late Effects of Treatment for Brain Tumors. Cancer Treatment and Research, vol 150. Springer, Boston, MA. https://doi.org/10.1007/b109924_13

Download citation

  • DOI: https://doi.org/10.1007/b109924_13

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-77102-1

  • Online ISBN: 978-0-387-77103-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation